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Abstract
Aims Pulmonary arterial hypertension (PAH) is common amongst patients with congenital heart disease (CHD). It is a severe
and complex condition that adversely affects quality of life and prognosis. While quality of life questionnaires are routinely
used in clinical pulmonary hypertension practice, little is known on how to interpret their results and manage PAH-CHD pa-
tients with evidence of impaired health-related quality of life, especially those with advanced disease and palliative care
needs.
Methods and results We performed a systematic review of studies concerning palliative care for people with PAH-CHD, also
reviewing the health-related quality of life literature pertaining to these patients. Of 330 papers identified through initial
screening, 17 were selected for inclusion. Underutilization of advance care planning and palliative care resources was
common. Where palliative care input was sought, this was frequently late in the course of the disease. No studies provided
evidence-based clinical criteria for triggering referral to palliative care, a framework for providing tailored care in this patient
group, or how to manage the risk of sudden cardiac death and implantable cardioverter defibrillators in advanced PAH-CHD.
We synthesize this information into eight important areas, including the impact of PAH-CHD on quality of life, barriers to and
benefits of palliative care involvement, advance care planning discussions, and end-of-life care issues in this complex patient
group, and provide expert consensus on best practice in this field.
Conclusions This paper presents the results of a systematic review and expert statements on the preferred palliative care
strategy for patients with PAH-CHD.
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Introduction
Pulmonary arterial hypertension (PAH) is prevalent in pa-
tients with congenital heart disease (CHD).1 It is typically
the result of a large systemic-to-pulmonary shunt in infancy
that has caused pulmonary vascular disease and hence a rise
in pulmonary arterial pressures. PAH is associated with in-
creased morbidity and mortality and significantly impacts
on patients’ health-related quality of life (HR-QoL) for a range
of physical and mental domains: reduced physical function-
ing, symptoms at rest and during exertion, impact on social
functioning and employment, side effects from PAH thera-
pies, uncertainty about prognosis, anxiety, and depression.2–9
Palliative care provides treatment and support for people
with life-limiting illnesses, aimed at improving their HR-QoL
and reducing symptom burden for patients and their families.
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Palliative care is relevant to patients with PAH related to CHD
(PAH-CHD), who may be young but highly symptomatic. To
date, there is limited evidence to guide palliative and end-
of-life (EOL) care for PAH-CHD patients. International guide-
lines recommend that physicians should be proactive in
discussing advance directives and EOL issues with these pa-
tients, along with seeking consultation from palliative care
specialists, when appropriate.10–12
The unique characteristics of the PAH-CHD population
should be recognized when designing palliative care services
for these patients (Figure 1). These include a wide age range,
severe symptom burden, limited therapeutic options,
significant morbidity relating to a combination of PAH, CHD,
and chronic cyanosis, multiorgan involvement, and comorbid-
ity, including learning difficulties. Physicians looking after
these complex patients require high levels of expertise;
hence, care is typically provided within highly specialized cen-
tres. PAH-CHD physicians should work closely with palliative
care teams, identifying the right time to seek palliative care
support and facilitate and adhere to palliative care and EOL
plans.
We present an expert statement on the role of palliative
care in PAH-CHD patients, based on the results of a system-
atic review of available evidence.
Figure 1 The palliative care framework for patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) should
take into account the unique characteristics and natural history of this condition. PAH-CHD can be a rapidly progressive disease, affecting both quality
of life (QoL) and prognosis. PAH therapies have now become integral to the management of most patients and are often escalated, aiming at a reduc-
tion in morbidity and mortality, and improvement in QoL. Despite this, patients can remain highly symptomatic; the early introduction of advance care
planning (ACP) and palliative care can help to alleviate the impact of the disease and agree treatment goals with patients. The onset of congestive
heart failure (HF) and/or progression of symptoms should further prompt palliative care involvement in parallel to escalation of PAH therapies (if ap-
propriate) and transplant assessment. The palliative care framework and resources for PAH-CHD patients should reflect the natural history of this dis-
ease, integrating components of acquired HF and lung disease care, but accounting for important differences: PAH-CHD is an often-aggressive disease
with early onset of symptoms, especially in ES patients, and a high prevalence of multiorgan involvement. Moreover, PAH-CHD patients are younger,
with a different impact of the disease on their lives compared with older patients (school/studies/work/sport, etc.).
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Methods
The UK-based Congenital Heart disease And pulMonary arte-
rial hyPertension: Improving Outcomes through education
and research Networks (CHAMPION) programme has a remit
of improving the care of patients with PAH-CHD by
supporting clinical decision making, including by identifying
gaps in evidence and areas of need in PAH-CHD. We identi-
fied palliative care as one such area of need,13 and this sys-
tematic review was used, together with expert opinion, to
provide a proposed framework for providing palliative care
in the adult PAH-CHD population.
A series of questions around the role and provision of pal-
liative care in PAH-CHD was agreed upon and a systematic re-
view of all published reports related to palliative care in
PAH-CHD was performed following the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
guidelines. This was supplemented by a review of the litera-
ture on the assessment of HR-QoL in PAH-CHD. Following
data synthesis, recommendations were drawn up by the
CHAMPION Steering Committee for each section of this
review. The systematic review methodology, including search




Our search identified 330 papers relevant to one or more of
the selected topics, of which 263 were excluded after title
and abstract screening based on the pre-specified exclusion
criteria (supporting information, Figure S1). The remaining
67 papers underwent full-text review, of which 50 further pa-
pers were excluded. The final group of 17 papers underwent
detailed screening for information (Figure S2).
Question 1: How does PAH-CHD affect quality of life and
which quality of life measures are most meaningful for and
applicable to patients with PAH-CHD?
Pulmonary arterial hypertension associated with congenital
heart disease can develop at any stage of a patient’s life,
overlaying one chronic disease on another. Patients with
CHD who develop PAH have a poorer exercise tolerance,
greater symptom burden, and poorer survival than other
CHD patients.2,3 Altered physical functioning is compounded
by impairments in other HR-QoL domains, including psycho-
logical and emotional well-being, and social functioning.
Generic HR-QoL measures, such as the Medical Out-
comes Study Short Form-36 (SF-36), and disease-specific
HR-QoL measures, such as the Cambridge Pulmonary Hyper-
tension Outcome Review (CAMPHOR) and emPHasis-10
questionnaires, have been employed in clinical trials involving
PAH-CHD patients (Table 1). HR-QoL in patients with
PAH-CHD correlates with clinical variables, such as New York
Heart Association functional class and 6 -minute walk dis-
tance, but not haemodynamic parameters.4,5 The majority
of studies have focussed on patients with Eisenmenger syn-
drome, in whom the combination of severe pulmonary vascu-
lar disease and long-standing cyanosis results in severe
exercise intolerance.6,7 Indeed, exercise performance and
HR-QoL is more impaired in Eisenmenger syndrome than in
complex cyanotic CHD patients with pulmonary stenosis
who have not developed severe pulmonary vascular disease.8
Studies of PAH therapies that use HR-QoL as a clinical
endpoint are limited to a few small open-label studies, which
support the HR-QoL-enhancing effect of PAH therapies.4,14–20
Nevertheless, HR-QoL has also been shown to be adversely
affected by the side effects of PAH therapies, especially
continuous prostanoid infusions, and the requirement for
frequent hospital contacts needed to monitor therapies in
patients with idiopathic PAH21; this is also likely to be the
case in PAH-CHD. Moreover, almost a quarter of adult pa-
tients with Eisenmenger syndrome in contemporary cohorts
have Down syndrome, which is associated with learning diffi-
culties, obesity, and sleep apnoea, amongst other comorbidi-
ties, all of which impact on HR-QoL and its measurement.
Patients with Down syndrome have often been excluded
from clinical studies, especially those involving self-rating
scales and questionnaires. Unlike other patients with PAH-
CHD, HR-QoL improvements have not been shown in this
group.15,16,18,22
Expert statement The HR-QoL of PAH-CHD patients is
affected by a combination of PAH, the congenital heart de-
fect, coexisting syndromes, and other comorbidities, such as
learning difficulties. We recommend that HR-QoL measures
should be developed and validated specifically for patients
with PAH-CHD, to reflect overall life satisfaction, and both
physical and mental domains of HR-QoL.23 Moreover, improv-
ing HR-QoL should be a major target for the management of
PAH-CHD patients, gathering information from both the
patient and their family or caregivers about their physical,
psychological, and social well-being, and establishing shared,
agreed treatment goals.
Question 2: When should palliative care be introduced and
what clinical indications should trigger a palliative care re-
ferral in patients with PAH-CHD?
Rather than being an EOL intervention, it is now acknowl-
edged that palliative care should be introduced earlier as an
approach to therapy aimed at improving QoL for patients
and their families ‘through the prevention and relief of suffer-
ing by early identification and impeccable assessment and
treatment of pain and other problems, physical, psychosocial
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and spiritual’.24 In oncology, early involvement of palliative
care improves overall HR-QoL and mood.25
Our systematic review indicates that palliative care input is
often sought late in the course of disease of patients with
PAH and CHD.26–29 Even though the majority of surveyed
patients with CHD (with complex or simple lesions) prefer
to be informed about their disease course before they face
life-threatening complications, even patients with advanced
or complex disease may not be offered palliative care at the
right time, or at all.30–32 The systematic review identified pu-
tative clinical indications for palliative care input in patients
with PAH and/or CHD, linked to management issues that
were either commonly encountered, less well-managed by
the primary team or where prognosis was guarded. For exam-
ple, Swetz et al. assessed the HR-QoL of PAH patients and
found that many patients had a ‘profound and multifactorial
symptom burden’ that adversely impacted HR-QoL and some-
times persisted even with optimal PAH therapy.26 Despite
this, few (<5%) patients were receiving palliative care or pain
management input. Another study identified two areas of
clinical management that the vast majority of physicians in-
volved in the clinical care of patients with PAH were not ‘very
comfortable’ managing, namely, HR-QoL and issues around
pain. Hence, patients who have been identified as having a
lower HR-QoL or pain complex management needs, for
example, requiring opioids, antidepressants, or other
neuromodulators, could be highlighted for palliative care
involvement.27 Apart from symptom management, other
issues addressed at initial palliative care consultation may
inform the timing and indications of palliative care referrals.
In a study of children with advanced heart disease, including
CHD, palliative care input tackled goals of care, provision of
psychological support, and advance care planning (ACP).28
Finally, in infants with complex CHD, for example, hypoplastic
left heart syndrome, where there is still a high initial
mortality, almost one half of congenital cardiothoracic
surgeons were in favour of palliative care referral at prenatal
diagnosis.29
Unfortunately, despite these studies pointing to possible
indications for palliative care referral in PAH and in children
with CHD, the systematic review identified no studies that
identify robust clinical criteria, which should trigger referral
for palliative care in patients with PAH-CHD.
Expert statement A ‘parallel planning’ approach to palliative
care is recommended for patients with PAH-CHD, with pallia-
tive care referral and assessment performed early, alongside
active multidisciplinary management and treatment with
PAH therapies (Figure 1).33 There is little evidence to guide
the timing of palliative care referral in this population in
terms of clinical indications. Markers of advanced disease,
such as the initiation of parenteral PAH therapy or referral
for transplant assessment, should certainly trigger a referral
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group who are often highly symptomatic at diagnosis and
who might not be candidates for these two treatment op-
tions. Transition to adult care is a key moment for discussing
future treatments and prognosis, and the availability and po-
tential benefits of concurrent palliative care input should be
discussed at this point.
Question 3: Who should initiate discussions about the role of
palliative care and advance care planning? How should
these discussions be broached?
The systematic review identified two studies where it was
noted that most patients prefer ACP and palliative care dis-
cussions and information to come from their specialist com-
pared with another cardiologist or their primary care
provider.31,34 The majority of patients were willing to speak
to a palliative care specialist, although none of the studies di-
rectly compared patient preferences regarding the involve-
ment of palliative care in ACP, in addition to or place of the
specialist care provider. The privileged position of PAH-CHD
specialists, providing long-term, often lifelong, care for their
patients, allows a strong rapport and a sense of collaborative
decision making to be formed over time. This was reflected
by several studies reporting the willingness of most patients
to discuss future goals, plans, and expectations with their
specialist physician earlier in the disease course, including in-
formation about the average life expectancy for patients with
their heart condition and EOL issues.31,32,35,36
To achieve this, PAH-CHD specialists need to be supported
with adequate resources and training, including advanced
communication skills, to initiate ACP conversations. In one
survey of adult CHD care providers, the vast majority (87%)
were interested in communication strategies for ACP discus-
sions, with almost as many (79%) reporting that it would be
helpful to have more information and resources on the sub-
ject. Kovacs et al. have produced recommendations to en-
hance conversations around ACP in adult CHD patients.37
There is an emphasis on sufficient time, space, and privacy
for these important discussions, hence scheduling a specific
visit to discuss goals of care and EOL care. Introducing such
conversations as ‘routine discussions’ that are made ‘with
all patients’ helps to normalize them. Open questions must
be used to discover what patients understand about their
condition and are willing to talk about, as well as to confirm
that they comprehend the issues discussed. Such discussions
are complex and often require more than one visit to com-
plete. Once agreed, careful documentation of the patient’s
wishes is key.
Expert statement Palliative care discussions should be initi-
ated by PAH-CHD specialists, seeking help from palliative care
specialists. The communication style and the topics covered
should be individualized, tailored to the age of the patient,
their underlying condition, and the coexistence of mental
health problems or learning difficulties. End-stage patients
who have greater palliative care needs should be managed
in joint multidisciplinary clinics in specialist PAH-CHD centres,
offering support from clinical nurse specialists, CHD specialist
physicians with an interest in advanced disease, palliative
care specialists, social workers, family support, and pastoral
care workers. For this approach to be successful, healthcare
providers should receive education and training on the role
of palliative care early in their career, which continues during
their training.
Question 4: What are the barriers to palliative care involve-
ment in the PAH-CHD population?
The systematic review identified several studies that address
potential obstacles to palliative care involvement, summa-
rized as patient-related, physician-related or healthcare-
related (Figure 2).13,26,27,29,31,32,34,36 Misconceptions by
patients, families, and healthcare practitioners of the role of
palliative care are common. It is often presented by
professionals as equivalent to EOL care and, thus, synony-
mous with ‘giving up’, or being incompatible with active
life-prolonging PAH treatments.27,29 Difficulties in defining
the prognosis for patients with PAH-CHD, for example, adults
with Eisenmenger syndrome, were also identified as a major
barrier.26
Even when CHD physicians believe that they discuss life ex-
pectancy, ACP, and resuscitation preferences with their pa-
tients routinely, their perceptions of performance are very
different to those of their patients. Tobler et al. found that
50% of providers, but only 1% of patients, surveyed indicated
that they had discussed EOL planning,31 even though the ma-
jority (76%) of patients stated they were ready to discuss
ACP, regardless of the severity of their underlying CHD.36
Organizational barriers to effective palliative care have not
been studied but are also a major barrier. In the UK, a survey
conducted by the CHAMPION group found that 81% of re-
sponders felt there was a lack of formal palliative care ser-
vices for PAH-CHD patients. Recommendations for changes
in practice have been formulated for patients with CHD, as
well as those with advanced lung disease or acquired heart
failure.33,37–40
Expert statement Several barriers still exist resulting in the
underutilization of palliative care resources for PAH-CHD.
Lines of communication with specialist palliative care teams
need to be strengthened to align goal setting, information
sharing, and decision making between teams. This calls for
a palliative care presence at PAH-CHD clinical multidisciplin-
ary meetings, where management strategies are discussed,
as well as joint consultations between PAH-CHD and palliative
care specialists in clinics attended by patients with advanced
disease.
A shared care framework can improve palliative care provi-
sion without placing unreasonable demands on existing re-
sources. Such a model has been proposed by Moynihan
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et al. for use in paediatric cardiac intensive care units,41
which can easily be applied to the adult PAH-CHD service.
The model relies on the selection and training of interdisci-
plinary palliative care ‘champions’. This group of healthcare
professionals should include psychologists, senior nurse prac-
titioners, cardiologists, cardiac intensivists, surgeons, and al-
lied health professionals, who receive additional palliative
care training through courses and subspecialty rotations. In
turn, this group of professionals strengthens palliative care
provision through training of other staff, creating palliative
care pathways, and developing quality improvement initia-
tives. They should liaise between PAH-CHD, palliative care,
and interdisciplinary support staff on an individual basis de-
pending on case complexity and specific needs. This type of
model can extend the reach of palliative care using current
numbers of palliative care specialists, through local educa-
tion, training, and empowerment.
At the same time, education for patients, families,
healthcare providers, and also policy makers is key to
overcome barriers to palliative care by addressing common
misconceptions of palliative care and empowering shared
goal setting and decision making. The process of educating
ourselves and our patients cannot be purely opportunistic,
relying on the ‘right moment’ arising in clinic. Rather, struc-
tured education at clinic appointments designed for this pur-
pose, through patient groups and using digital platforms and
new technologies is necessary. For healthcare professionals
looking after patients with PAH-CHD, clear pathways for
how and when to access palliative care resources (tailored
to the local resources available at each trust) should be
available. They should be coupled with communication
training and opportunities for further professional education
for those with a special interest in palliative care. This
should be strengthened at a national and international level
by clear guidelines for palliative care in PAH-CHD and pro-
motion of quality improvement and research to improve
the evidence base for palliative care provision in this
population.
Figure 2 Barriers to effective palliative care involvement, involving different stakeholders of PAH-CHD care, and recommendations for adapting care
towards successful integration and provision of palliative care. +Misconceptions surrounding palliative care include the belief that palliative care is
equivalent to end-of-life or hospice care, that is, it equates to ‘giving up’ or ‘losing hope’, is incompatible with active PAH therapy and is exclusively
the remit of palliative care specialists. ACP, advanced care planning; EOL, end-of-life; PAH-CHD, pulmonary arterial hypertension associated with
congenital heart disease; PC, palliative care.
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Question 5: What are the potential benefits and treatment
targets for patients and their families of palliative care
involvement?
The importance of palliative care in chronic illness, including
in PAH and acquired heart failure, has been highlighted in
several reviews, and benefits include minimizing symptoms
and burdensome therapies while maximizing HR-QoL, psycho-
logical well-being, independence, and social functioning.33 In
acquired heart failure patients, the effect of palliative care in-
terventions was studied recently in the PAL-HF trial. Patients
were randomized to conventional heart failure management
alone or with integrated, interdisciplinary palliative care. The
latter afforded a benefit in heart-failure-related and overall
HR-QoL parameters.42 Yet, there remains a paucity of clinical
studies testing the impact of palliative care interventions in
PAH and PAH-CHD. Our review yielded only one study
designed to test a palliative care intervention in all-comers
attending heart failure and transplant clinic, including patients
with CHD. In this quality-improvement project, training in ACP
discussions increased the rate of documented ACP discussions
from 0% to 75% over the 2 year study period.43
Regardless, patients and their families often have clear
ideas about their objectives when palliative care is involved.
In a study of children with advanced heart disease receiving
palliative care review, including patients with CHD, two-thirds
of families stated that their primary goal was for their child to
live as long and as comfortably as possible. Improved survival
with comfort is compatible with the concept of ‘parallel plan-
ning’. Children whose families stated that comfort was their
primary goal at EOL were less likely to die in an intensive care
unit, and more likely to die in a comfort care setting, with no
life-sustaining treatment.28
Expert statement The benefits of timely, integrated pallia-
tive care involvement go beyond symptom relief, providing
physical, psychological and social support for patients with
serious illness and their families or caregivers (Figure 3).
Moreover, palliative care aims to improve the HR-QoL of all
those affected by the condition, both patients and their
families. Despite the paucity of data measuring the benefits
of palliative care in PAH-CHD, palliative care has the potential
to improve the lives of patients and their families,
especially when care is provided in a framework where
palliative care can be effectively integrated with specialist
medical care.
Figure 3 Multidimensional facets and goals of palliative care involvement. QoL, quality of life.
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Question 6: Should there be a different framework for pro-
viding palliative care to PAH-CHD patients, compared with
other services?
In the absence of specialized palliative care services for PAH-
CHD, patients often have to fit into acquired heart failure or
chronic obstructive pulmonary disease services. This does
not allow the creation of a tailored service, nor does it serve
the unique features of the PAH-CHD population, who are typ-
ically young, often diagnosed prenatally with CHD, and may
have complex comorbidities relating to pulmonary hyperten-
sion, residual haemodynamic defects, long-standing cyanosis,
and other syndromes. There are differences in symptom
prevalence and severity between PAH and other disorders
where palliative input is often sought, with a higher preva-
lence of exertional dyspnoea, fatigue, and palpitations than
similar studies in patients receiving cancer therapy.44 The
EOL experiences of PAH-CHD patients are also likely to differ
from other patient groups. For example, compared with pa-
tients with cancer, adults with CHD were more likely to have
an inpatient or intensive care admission in the last 30 days of
life.45 Similarly, children with CHD were likely to die during
withdrawal of life-sustaining interventions (78%), with par-
ents realizing that their child had no realistic chance of sur-
vival a median of 2 days before death.46 For PAH-CHD
patients, who have often received care from the same con-
genital heart team since birth, it can be difficult, if not inap-
propriate, to ‘transition patient care to another group of
providers as EOL approaches’.47
Expert statement Palliative and EOL care services that target
the specific needs of PAH-CHD patients are desirable.13
Hence, a PAH-CHD palliative care framework should (i) be
able to cater for patients of all ages, (ii) combine elements
of cardiac and respiratory palliative care, and (iii) integrate
fully into current PAH-CHD care. Care goals, expectations,
and service delivery need to be aligned between specialities
and be appropriate for the age and level of maturity of the
individual patient (Figure 1). The transition period, between
paediatric and adult services, can be seen as a ‘key moment’
for identifying ideal candidates for palliative care input, initi-
ating a discussion about expectations and ACP.40
Palliative care services for PAH-CHD patients should inte-
grate components of palliative care designed for advanced
lung disease or heart failure.39 Pulmonary rehabilitation and
the creation of individualized action plans can help improve
the management of dyspnoea crises, with learning from
cardiac palliative care on the management of patients with
congestive heart failure. Lessons can be learned also from
both lung and cardiac palliative care with regard to
polypharmacy and coping with multiple therapies with signif-
icant side effects, the impact of transplantation listing and/or
long-term mechanical circulatory support and decisions
regarding EOL and withdrawal of treatments.48
A lead doctor and named nurse should be chosen to
oversee EOL care for each patient,49 but close partnership
with palliative care specialists with an interest in chronic
cardiopulmonary disease and life-limiting disease affecting
younger patients is imperative to allow the best possible
use of palliative care resources. We can draw from the
experience of specialities who look after young patients with
lifelong respiratory diseases,50 such as cystic fibrosis, where a
speciality-led palliative care model is used, in which the spe-
cialist cystic fibrosis team meet the majority of the palliative
care needs of their patients, following established pathways
and guidelines, and refer to palliative care specialists in com-
plex cases when additional support is needed.51
Question 7: What can palliative care offer towards the end of
life? What is the role of advance decisions and DNACPR
orders in this group?
ACP is the process by which a patient’s wishes and EOL care
preferences are discussed and agreed upon. Early, effective
communication practices around goals of therapy and the risk
of complications can set the stage for subsequent, more in-
volved conversations about prognosis, patients’ wishes and
preferences. Steiner et al. found that adult CHD inpatients
had a significantly greater resource utilization, with a higher
rate of hospital and intensive care unit admissions towards
the EOL compared with patients with cancer or acquired heart
failure.45 The same study found that adult CHD patients were
more likely to have an ACP in place than cancer patients, al-
though the systematic review identified variable rates of ACP
depending on the setting and cohort. However, in the outpa-
tient setting, ACP is much less frequent. In another study on
adults with CHD, EOL discussions had occurred in only 6% of
patients prior to their terminal admission. Even during the
terminal admission, the majority of discussions took place late
in the hospital stay, at a median of 2 days before death. At this
point, conversations are much more likely to focus on
de-escalation of therapy than patients’ wishes and HR-QoL
enhancement.52 Moreover, this close to death, many patients
lose capacity and conversations are more likely to be had with
the family and carers. Tobler et al. previously reported on a
group of hospitalized adults with CHD; immediately prior to
death, 44% of patients were receiving mechanical ventilation,
while over half (52%) died under attempted resuscitation.52
The systematic review did not identify any studies exploring
the associated question of whether specific invasive therapies
where discussed as part of ACP and how often ACP decisions
were followed at the point of an acute deterioration.
Pulmonary arterial hypertension patients who suffer from
cardiac arrest rarely survive, making successful cardiopulmo-
nary resuscitation very unlikely. Hence, Do Not Attempt
Cardiopulmonary Resuscitation (DNACPR) discussions will be
appropriate for patients with advanced disease and should,
ideally, be anticipatory, undertaken by senior physicians,
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sensitive to the wishes and concerns of the patient and their
family, and in the wider context of ACP.53
Expert statement Well-timed, sensitive, open communica-
tion with patients and their families is essential. Discussions
have to take into account the patient’s age, level of under-
standing, and emotional readiness to take on information
about prognosis, treatment goals, resuscitation, and plans
for EOL care. Patients must be made aware of EOL services
and palliative care options. Patient preferences and wishes
about their future care should be documented clearly in their
notes and can be recorded formally as advance decisions to
refuse treatment (Table 2). For patients who do not wish to
make an advance decisions to refuse treatment, ‘advance
statements’ can be helpful, allowing patients to organize their
thoughts about their wishes and preferences around any
aspect of their future care. In order to be useful, patient pref-
erences should be specific and reflect the choices they are
likely to be faced with if their clinical status deteriorates
in-hospital or at home, acknowledging that many patients
who deteriorate acutely in hospital may become too unwell
to be discharged to their preferred place of death. This re-
quires clinicians to provide patients with adequate informa-
tion, in an honest and easy to understand manner, which
allows them to make their choices. Only a minority of patients
will not be ready for such conversations or prefer not to talk
about the terminal phase of their illness. In such cases, it is im-
portant to highlight the need for planning and suggest that pa-
tients might select a family member, carer, or friend to assist
them, or they may wish to appoint a lasting power of attorney
to make decisions for them, should they lose capacity. Ideally,
the clinical team should communicate directly with the pa-
tients when they have capacity and should ascertain their
wishes well before they lose capacity. Only when patients do
not have capacity to make decisions should family members
or carers be approached as the primary point of contact.
A DNACPR order should be discussed with PAH-CHD pa-
tients with advanced disease on maximal therapy with a
guarded prognosis, who are not on a transplant list.
Question 8: How should the risk of sudden cardiac death be
managed in PAH-CHD? What is the role of implantable
cardioverter defibrillators in this cohort?
Sudden cardiac death is not uncommon in patients with
CHD, including those with PAH.54 Previous studies identifying
predictors of mortality in PAH-CHD have not focused on
sudden arrhythmic events.55–57 A recent retrospective study
of patients with Eisenmenger syndrome has identified pre-
dictors of sudden cardiac death in this subgroup, but identi-
fying patients in the wider PAH-CHD population who may
benefit from automated implantable cardioverter defibrilla-
tor (ICD) implantation as primary prevention remains less
than straightforward.58 Moreover, the decision to proceed
to ICD implantation, even in secondary prevention, needs
to be individualized, to account for age, functional status, life
expectancy, and the expected mode of death, that is, ar-
rhythmic sudden cardiac death versus progressive ventricular
dysfunction or respiratory failure. Finally, ICD implantation
can be associated with complications, including a high risk
of lead-related complications of up to 25% over 10 years,
infective endocarditis, inappropriate shocks, and the need
for anticoagulation in patients with large intracardiac
Table 2 Advance care planning and the methods by which plans for future care can be set
Methods of instructing future care Description
Advance care planning A process that supports adults at any age or stage of health in understanding and
sharing their personal values, life goals, and preferences regarding future medical
care. The goal is to ensure that people receive medical care that is consistent with
their values, goals, and preferences during serious and chronic illness.a
Advance statement A written and signed statement, which sets out the patient’s preferences, wishes,
beliefs, and values regarding their future care. This may include any aspect of care,
including the location of care, preferences, and religious or spiritual beliefs.
Advance decision (living will or advance
decision to refuse treatment)
A legally binding document regarding a decision to refuse a named treatment
(including life-sustaining treatment) in a specific circumstance in the future.
Lasting power of attorney (LPA) for
Health and Welfare
The legal appointment of a personal welfare attorney who can make health and
welfare decisions on behalf of a person, when their capacity to make such
decisions is lost. If specified, this can include decisions about life-sustaining
treatments.
Do Not Attempt CPR (DNACPR) decision An anticipatory order, completed on a standardized form and shared between
healthcare professionals, which can provide immediate guidance on the best action
to take (or not take) should the person suffer a cardiac arrest. The decision can be
made in advance by a capacitous patient who wishes to refuse CPR, or as a result
of high-quality, timely communication by a doctor with a patient and their
surrogate (unless the patient has requested confidentiality or only the surrogate
where the person lacks capacity) based on the futility of CPR or the balance of
benefits/burdens of CPR.b
CPR, cardiopulmonary resuscitation.
aThe International Consensus Definition of Advance Care Planning.67
bModified from the guideline document from the British Medical Association, Resuscitation Council (UK) and the Royal College of
Nursing.53
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communications.59–61 Even in congenital cardiac conditions
where risk factors for sudden cardiac death have been iden-
tified (e.g. tetralogy of Fallot), the mortality benefit of ICDs is
yet to be demonstrated.11
Expert statement The role of ICDs for primary or secondary
prevention remains unclear in PAH and a question for future
research. When contemplating ICD implantation, physicians
should consider the patient’s life expectancy (ideally
>1 year), their functional class (to be avoided in those in
functional Class IV who are not candidates for transplanta-
tion), and individualized risks of device complications and
anticoagulation.62 Hence, ICD insertion may not be appropri-
ate for many patients with advanced PAH-CHD. For patients
who have an ICD and are approaching the later stages of their
disease, discussions about ICD deactivation should form part
of ACP. These concepts should ideally be discussed at the
time of ICD implantation. In patients nearing EOL, ICD deacti-
vation should be part of the DNACPR discussion, when at-
tempts at CPR are considered inappropriate and HR-QoL is
the primary aim.63
Discussion
Early adoption of palliative care practices in patients with
PAH-CHD, including HR-QoL assessment and ACP, promotes
a holistic approach to care, which optimizes physical and emo-
tional well-being. Palliative care should be part of the training
of all PAH-CHD providers, who should address the palliative
care needs of their patients in close collaboration with pallia-
tive care specialists. A multidisciplinary approach to palliative
care for PAH-CHD patients can target intractable symptoms
and address complex issues, discordant patient–family goals,
and unrealistic expectations of prognosis or treatment
effects.40 Integrating palliative care strategies into the ongo-
ing, active management of PAH-CHD patients challenges the
concept of palliative care as an EOL intervention. Instead, it
allows the provision of continuous, high-quality parallel
planning during the gradual shift from life-prolonging therapy
towards palliation.
In this review, we provide expert opinion on important
topics relating to palliative care in PAH-CHD, based on the
findings of a systematic review of published studies. Palliative
care remains an underutilized resource in this population, and
barriers to effective palliative care adoption and utilization
still need to be overcome. Education of existing healthcare
providers and empowerment of patients through an open di-
alogue is key to capitalize on available resources. Frequent
discussions about current milestones and future goals, with
appropriately timed ACP conversations, encourage timely
shared decision making. PAH-CHD specialists need to be
aware of available palliative care resources and must be able
to perform parallel planning when escalating PAH therapies,
considering referral to transplantation, preventing and ag-
gressively treating complications that may arise, but should
also ensure that their treatment choices do not weigh heavily
on the QoL of the patient.
Ultimately, this young, highly complex patient group does
not fit the mould of many other disease groups requiring pal-
liative care input, and existing palliative care pathways and
guidelines should be combined and refined, based on our un-
derstanding of the pathophysiology and management of
PAH-CHD, in order to optimize patient care from a prognostic
and HR-QoL point of view.
Study limitations
This body of work has important limitations, primarily related
to the limited evidence in terms of the number of papers and
quality of evidence on HR-QoL measures and palliative care
interventions in this group of patients. The primary scope of
the search was to inform expert opinion rather than to pro-
vide a completely evidence-based recommendation. There
is urgent need for research in this area, as demonstrated by
the scarcity of evidence on this important clinical topic.
Conclusions
Pulmonary arterial hypertension associated with congenital
heart disease is a life-limiting condition with a high symptom
burden and reduced HR-QoL. Improving palliative care provi-
sion in this complex group of patients involves better educa-
tion, treatment coordination, and direction of resources.
Palliative care should be a collaborative effort between
PAH-CHD experts and palliative care specialists, provided in
centres with adequate expertise in the management of both
PAH and CHD. The paucity of studies on HR-QoL and palliative
care in PAH-CHD calls urgently for multicentre collaboration
and hypothesis-driven research to further guide clinical
practice.
Acknowledgements
We would like to acknowledge Professor Karen Forbes,
Consultant in Palliative Care, University Hospitals Bristol and
Weston NHS Foundation Trust for her valuable comments
on our manuscript. Medical writing support for this manu-
script was provided by nspm ltd., Meggen, Switzerland.
Eleanor Hobbs (nspm ltd.) acted as an independent reviewer
for the systematic review.
Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion 11
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13263
Conflict of interest
All authors have been consultants to and have received grant
support and personal fees from Janssen-Cilag Limited during
the conduct of the study. Dr Condliffe has received personal
fees from Bayer and GlaxoSmithKline. Dr Clift has received
personal fees from Bayer. Professor Tulloh has received per-
sonal fees from Pfizer, Abbott International, GlaxoSmithKline,
and Bayer. Professor Dimopoulos has received grants and
personal fees from Pfizer, GlaxoSmithKline, and Bayer/MSD.
Funding
The manuscript was funded by Janssen-Cilag Limited, who
had no influence on manuscript writing.
Author contributions
All authors contributed to the conception and design of the
work as the CHAMPION steering committee. A.C. and K.D.
performed the systematic review, data extraction, and inter-
pretation. A.C. drafted the manuscript with input from all
authors. K.D., R.C., P.C. and R.T. critically revised the manu-
script. All authors gave final approval and agree to be ac-
countable for all aspects of work ensuring integrity and
accuracy.
Sources of support
Medical writing support for this manuscript was provided by
nspm ltd, Meggen, Switzerland and funded by Janssen-Cilag
Limited, who had no influence on manuscript writing.
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Systematic review inclusion and exclusion criteria.
Figure S2. Flow diagram showing the stages involved in
choosing eligible publications for the systematic review
(modified from the PRISMA recommendations).
References
1. Duffels MGJ, Engelfriet PM, Berger RMF,
van Loon RLE, Hoendermis E, Vriend
JWJ, van der Velde ET, Bresser P, Mulder
BJM. Pulmonary arterial hypertension in
congenital heart disease: an epidemio-
logic perspective from a Dutch registry.
Int J Cardiol 2007; 120: 198–204.
2. Engelfriet PM, Duffels MGJ, Möller T,
Boersma E, Tijssen JGP, Thaulow E,
Gatzoulis MA, Mulder BJM. Pulmonary
arterial hypertension in adults born with
a heart septal defect: the Euro Heart
Survey on adult congenital heart dis-
ease. Heart 2007; 93: 682–687.
3. Lowe BS, Therrien J, Ionescu-Ittu R,
Pilote L, Martucci G, Marelli AJ. Diagno-
sis of pulmonary hypertension in the
congenital heart disease adult popula-
tion impact on outcomes. J Am Coll
Cardiol 2011; 58: 538–546.
4. Cha KS, Cho KI, Seo JS, Choi JH, Park
YH, Yang DH, Hong GR, Kim DS. Effects
of inhaled iloprost on exercise capacity,
quality of life, and cardiac function in
patients with pulmonary arterial hyper-
tension secondary to congenital heart
disease (the Eisenmenger syndrome)
(from the EIGER Study). Am J Cardiol
2013; 112: 1834–1839.
5. Amedro P, Basquin A, Gressin V, Clerson
P, Jais X, Thambo JB, Guerin P, Cohen S,
Bonnet D. Health-related quality of life
of patients with pulmonary arterial
hypertension associated with CHD: the
multicentre cross-sectional ACHILLE
study. Cardiol Young 2016; 26:
1250–1259.
6. Diller G-P, Dimopoulos K, Okonko D, Li
W, Babu-Narayan SV, Broberg CS,
Johansson B, Bouzas B, Mullen MJ,
Poole-Wilson PA, Francis DP, Gatzoulis
MA. Exercise intolerance in adult
congenital heart disease: comparative
severity, correlates, and prognostic
implication. Circulation 2005; 112:
828–835.
7. Dimopoulos K, Okonko DO, Diller G-P,
Broberg CS, Salukhe TV, Babu-Narayan
SV, Li W, Uebing A, Bayne S, Wensel R,
Piepoli MF, Poole-Wilson PA, Francis
DP, Gatzoulis MA. Abnormal ventilatory
response to exercise in adults with con-
genital heart disease relates to cyanosis
and predicts survival. Circulation 2006;
113: 2796–2802.
8. Müller J, Hess J, Hager A. Exercise per-
formance and quality of life is more im-
paired in Eisenmenger syndrome than
in complex cyanotic congenital heart
disease with pulmonary stenosis. Int J
Cardiol 2011; 150: 177–181.
9. Lewis R, Armstrong I, Bergbaum C,
BrewisMJ, Cannon J, Charalampopoulos
A, Church AC, Coghlan JG, Davies RJ,
Dimopoulos K, Elliot C, Gibbs JSR,
Gin-SingW, Haji G, Hameed AG, Howard
LS, Johnson MK, Kempny A, Kiely DG,
Giudice FL, McCabe C, Peacock AJ,
Peleyeju O, Pepke-Zaba J, Polwarth G,
Price L, Sabroe I, Schreiber BE, Sheares
K, Taboada D, Thompson AAR, Toshner
MR, Wanjiku I, Wort SJ, Yorke J,
Condliffe R. EmPHasis-10 health-related
quality of life score predicts outcomes in
patients with idiopathic and connective
tissue disease-associated pulmonary ar-
terial hypertension: results from a UK
multi-centre study. Eur Respir J 2020.
https://doi.org/10.1183/13993003.001
24-2020
10. Galiè N, Humbert M, Vachiery J-L, Gibbs
S, Lang I, Torbicki A, Simonneau G, Pea-
cock A, Vonk Noordegraaf A, Beghetti M,
Ghofrani A, Gomez Sanchez MA,
Hansmann G, Klepetko W, Lancellotti P,
Matucci M, McDonagh T, Pierard LA,
Trindade PT, Zompatori M, Hoeper M.
12 A. Constantine et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13263
2015 ESC/ERS Guidelines for the diag-
nosis and treatment of pulmonary hyper-
tension: The Joint Task Force for the
Diagnosis and Treatment of Pulmonary
Hypertension of the European Society
of Cardiology (ESC) and the European
Respiratory Society (ERS)Endorsed by:
Association for European Paediatric and
Congenital Cardiology (AEPC), Interna-
tional Society for Heart and Lung Trans-
plantation (ISHLT). Eur Respir J 2015;
46: 903–975.
11. Stout KK, Daniels CJ, Aboulhosn JA,
Bozkurt B, Broberg CS, Colman JM,
Crumb SR, Dearani JA, Fuller S, Gurvitz
M, Khairy P, Landzberg MJ, Saidi A,
Valente AM, van Hare G. 2018 AHA/
ACC Guideline for the Management of
Adults With Congenital Heart Disease: a
Report of the American College of Cardi-
ology/American Heart Association Task
Force on Clinical Practice Guidelines. Cir-
culation 2019; 139: e698–e800.
12. Baumgartner H, Bonhoeffer P, De Groot
NMS, de Haan F, Deanfield JE, Galie N,
Gatzoulis MA, Gohlke-Baerwolf C,
Kaemmerer H, Kilner P, Meijboom F,
Mulder BJM, Oechslin E, Oliver JM,
Serraf A, Szatmari A, Thaulow E, Vouhe
PR, Walma E, Task Force on the Man-
agement of Grown-up Congenital Heart
Disease of the European Society of Car-
diology (ESC), Association for European
Paediatric Cardiology (AEPC), ESC
Committee for Practice Guidelines
(CPG). ESC guidelines for the manage-
ment of grown-up congenital heart dis-
ease (new version 2010). Eur Heart J
2010; 31: 2915–2957.
13. Tulloh R, Dimopoulos K, Condliffe R,
Clift P. Management of adults with con-
genital heart disease and pulmonary ar-
terial hypertension in the UK: survey of
current practice, unmet needs and ex-
pert commentary. Heart Lung Circ
2018; 27: 1018–1027.
14. Ibrahim R, Granton JT, Mehta S. An
open-label, multicentre pilot study of
bosentan in pulmonary arterial hyper-
tension related to congenital heart dis-
ease. Can Respir J 2006; 13: 415–420.
15. Duffels MGJ, Vis JC, van Loon RLE,
Berger RMF, Hoendermis ES, van Dijk
APJ, Bouma BJ, Mulder BJM. Down pa-
tients with Eisenmenger syndrome: is
bosentan treatment an option? Int J
Cardiol 2009; 134: 378–383.
16. Duffels MGJ, Vis JC, van Loon RLE,
Nieuwkerk PT, van Dijk APJ,
Hoendermis ES, de Bruin-Bon RHACM,
Bouma BJ, Bresser P, Berger RMF,
Mulder BJM. Effect of bosentan on exer-
cise capacity and quality of life in adults
with pulmonary arterial hypertension
associated with congenital heart disease
with and without Down’s syndrome. Am
J Cardiol 2009; 103: 1309–1315.
17. Blok IM, van Riel ACMJ, Schuuring MJ,
Duffels MG, Vis JC, van Dijk APJ,
Hoendermis ES, Mulder BJM, Bouma
BJ. Decrease in quality of life predicts
mortality in adult patients with
pulmonary arterial hypertension due to
congenital heart disease. Neth Heart J
2015; 23: 278–284.
18. Vis JC, Duffels MG, Mulder P, de Bruin-
Bon RHACM, Bouma BJ, Berger RMF,
Hoendermis ES, van Dijk APJ, Mulder
BJM. Prolonged beneficial effect of
bosentan treatment and 4-year survival
rates in adult patients with pulmonary
arterial hypertension associated with
congenital heart disease. Int J Cardiol
2013; 164: 64–69.
19. Tay ELW, Papaphylactou M, Diller GP,
Alonso-Gonzalez R, Inuzuka R,
Giannakoulas G, Harries C, Wort SJ,
Swan L, Dimopoulos K, Gatzoulis MA.
Quality of life and functional capacity
can be improved in patients with
Eisenmenger syndrome with oral silden-
afil therapy. Int J Cardiol 2011; 149:
372–376.
20. Clavé MM, Maeda NY, Thomaz AM,
Bydlowski SP, Lopes AA. Phosphodies-
terase type 5 inhibitors improve micro-
vascular dysfunction markers in
pulmonary arterial hypertension associ-
ated with congenital heart disease.
Congenit Heart Dis 2019; 14: 246–255.
21. Rival G, Lacasse Y, Martin S, Bonnet S,
Provencher S. Effect of pulmonary arte-
rial hypertension-specific therapies on
health-related quality of life: a system-
atic review. Chest 2014; 146: 686–708.
22. Martínez-Quintana E, Miranda-Calderín
G, Ugarte-Lopetegui A, Rodríguez-
González F. Rehabilitation program in
adult congenital heart disease patients
with pulmonary hypertension. Congenit
Heart Dis 2010; 5: 44–50.
23. Moons P, Van Deyk K, Budts W, De Geest
S. Caliber of quality-of-life assessments
in congenital heart disease: a plea for
more conceptual and methodological
rigor. Arch Pediatr Adolesc Med 2004;
158: 1062–1069.




25. Temel JS, Greer JA, Muzikansky A,
Gallagher ER, Admane S, Jackson VA,
Dahlin CM, Blinderman CD, Jacobsen
J, Pirl WF, Billings JA, Lynch TJ. Early
palliative care for patients with metasta-
tic non–small-cell lung cancer. N Engl J
Med 2010; 363: 733–742.
26. Swetz KM, Shanafelt TD, Drozdowicz
LB, Sloan JA, Novotny PJ, Durst LA,
Frantz RP, McGoon MD. Symptom bur-
den, quality of life, and attitudes toward
palliative care in patients with
pulmonary arterial hypertension: results
from a cross-sectional patient survey. J
Heart Lung Transplant 2012; 31:
1102–1108.
27. Fenstad ER, Shanafelt TD, Sloan JA,
Novotny PJ, Durst LA, Frantz RP,
McGoon MD, Swetz KM. Physician atti-
tudes toward palliative care for patients
with pulmonary arterial hypertension:
results of a cross-sectional survey. Pulm
Circ 2014; 4: 504–510.
28. Marcus KL, Balkin EM, Al-Sayegh H,
Guslits E, Blume ED, Ma C, Wolfe J. Pat-
terns and outcomes of care in children
with advanced heart disease receiving
palliative care consultation. J Pain
Symptom Manage 2018; 55: 351–358.
29. Morell E, Thompson J, Rajagopal S,
Blume ED, May R. Congenital cardiotho-
racic surgeons and palliative care: a na-
tional survey study. J Palliat Care 2019;
36: 17–21.
30. Grinnan D, Swetz K, Pinson J, Lyckholm
L, Smith T. The end-of-life experience of
a cohort of patients with pulmonary ar-
terial hypertension. J Pain Symptom
Manage 2012; 43: 445–446.
31. Tobler D, Greutmann M, Colman JM,
Greutmann-Yantiri M, Librach LS,
Kovacs AH. End-of-life in adults with
congenital heart disease: a call for early
communication. Int J Cardiol 2012;
155: 383–387.
32. Tobler D, Greutmann M, Colman JM,
Greutmann-Yantiri M, Librach SL,
Kovacs AH. Knowledge of and prefer-
ence for advance care planning by
adults with congenital heart disease.
Am J Cardiol 2012; 109: 1797–1800.
33. Khirfan G, Tonelli AR, Ramsey J, Sahay
S. Palliative care in pulmonary arterial
hypertension: an underutilised treat-
ment. Eur Respir Rev 2018; 27: 180069.
34. Steiner JM, Stout K, Soine L, Kirkpatrick
JN, Curtis JR. Perspectives on advance
care planning and palliative care among
adults with congenital heart disease.
Congenit Heart Dis 2019; 14: 403–409.
35. Deng LX, Gleason LP, Khan AM,
Drajpuch D, Fuller S, Goldberg LA,
Mascio CE, Partington SL, Tobin L, Kim
YY, Kovacs AH. Advance care planning
in adults with congenital heart disease:
a patient priority. Int J Cardiol 2017;
231: 105–109.
36. Greutmann M, Tobler D, Colman JM,
Greutmann-Yantiri M, Librach SL,
Kovacs AH. Facilitators of and barriers
to advance care planning in adult con-
genital heart disease. Congenit Heart
Dis 2013; 8: 281–288.
37. Kovacs AH, Landzberg MJ, Goodlin SJ.
Advance care planning and end-of-life
management of adult patients with con-
genital heart disease. World J Pediatr
Congenit Heart Surg 2013; 4: 62–69.
38. Kirkpatrick JN, Kim YY, Kaufman BD.
Ethics priorities in adult congenital
heart disease. Prog Cardiovasc Dis
2012; 55: 266–273.e3.
39. Khateeb D, West F. Palliative manage-
ment and end-of-life care in nonmalig-
nant advanced lung disease. Clin Pulm
Med 2017; 24: 206–214.
40. Troost E, Roggen L, Goossens E, Moons
P, de Meester P, van de Bruaene A, Budts
W. Advanced care planning in adult con-
genital heart disease: transitioning from
repair to palliation and end-of-life care.
Int J Cardiol 2019; 279: 57–61.
41. Moynihan KM, Snaman JM, Kaye EC,
Morrison WE, DeWitt AG, Sacks LD,
Thompson JL, Hwang JM, Bailey V,
Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion 13
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13263
Lafond DA, Wolfe J, Blume ED. Integra-
tion of pediatric palliative care into car-
diac intensive care: a champion-based
model. Pediatrics; 144. Epub ahead of
print 2019: e20190160.
42. Rogers JG, Patel CB, Mentz RJ, Granger
BB, Steinhauser KE, Fiuzat M, Adams
PA, Speck A, Johnson KS,
Krishnamoorthy A, Yang H, Anstrom KJ,
Dodson GC, Taylor DH Jr, Kirchner JL,
Mark DB, O’Connor CM, Tulsky JA. Palli-
ative care in heart failure: the PAL-HF
randomized, controlled clinical trial. J
Am Coll Cardiol 2017; 70: 331–341.
43. Edwards LA, Bui C, Cabrera AG, Jarrell
JA. Improving outpatient advance care
planning for adults with congenital or
pediatric heart disease followed in a pe-
diatric heart failure and transplant clinic.
Congenit Heart Dis 2018; 13: 362–368.
44. Matura LA, McDonough A, Carroll DL.
Symptom prevalence, symptom severity,
and health-related quality of life among
young, middle, and older adults with
pulmonary arterial hypertension. Am J
Hosp Palliat Care 2014; 33: 214–221.
45. Steiner JM, Kirkpatrick JN, Heckbert SR,
Sibley J, Fausto JA, Engelberg RA,
Randall Curtis J. Hospital resource utili-
zation and presence of advance direc-
tives at the end of life for adults with
congenital heart disease. Congenit Heart
Dis 2018; 13: 721–727.
46. Blume ED, Balkin EM, Aiyagari R, Ziniel
S, Beke DM, Thiagarajan R, Taylor L,
Kulik T, Pituch K, Wolfe J. Parental per-
spectives on suffering and quality of life
at end-of-life in children with advanced
heart disease: an exploratory study*.
Pediatr Crit CareMed 2014; 15: 336–342.
47. Crossland DS, Van De Bruaene A,
Silversides CK, Hickey EJ, Roche SL.
Heart failure in adult congenital heart
disease: from advanced therapies to
end-of-life care. Can J Cardiol 2019; 35:
1723–1739.
48. Sobanski PZ, Alt-Epping B, Currow DC,
Goodlin SJ, Grodzicki T, Hogg K,
Janssen DJA, Johnson MJ, Krajnik M,
Leget C, Martínez-Sellés M, Moroni M,
Mueller PS, Ryder M, Simon ST, Stowe
E, Larkin PJ. Palliative care for people
living with heart failure: European Asso-
ciation for Palliative Care Task Force ex-
pert position statement. Cardiovasc Res
2020; 116: 12–27.
49. NHS Proposed Congenital Heart Disease
Standards and Service specifications -
NHS England - Citizen Space, https://
www.engage.england.nhs.uk/consulta-
tion/congenital-heart-disease-stan-
dards/ (accessed 31 May 2020).
50. Bowater SE, Speakman JK, Thorne SA.
End-of-life care in adults with congeni-
tal heart disease: now is the time to
act. Curr Opin Support Palliat Care
2013; 7: 8–13.
51. Bourke SJ, Doe SJ, Gascoigne AD,
Heslop K, Fields M, Reynolds D, Mannix
K. An integrated model of provision of
palliative care to patients with cystic
fibrosis. Palliat Med 2009; 23: 512–517.
52. Tobler D, Greutmann M, Colman JM,
Greutmann-Yantiri M, Librach LS,
Kovacs AH. End-of-life care in hospital-
ized adults with complex congenital
heart disease: care delayed, care denied.
Palliat Med 2012; 26: 72–79.
53. Guidance from the British Medical Asso-
ciation, the Resuscitation Council (UK)
and the Royal College of Nursing. Deci-
sions relating to cardiopulmonary resus-
citation, https://www.resus.org.uk/
EasySiteWeb/GatewayLink.aspx?alId=
16643 (2016, accessed 31 May 2020).
54. Daliento L, Somerville J, Presbitero P,
Menti L, Brach-Prever S, Rizzoli G,
Stone S. Eisenmenger syndrome. Factors
relating to deterioration and death. Eur
Heart J 1998; 19: 1845–1855.
55. Kempny A, Hjortshøj CS, Gu H, Li W,
Opotowsky AR, Landzberg MJ, Jensen
AS, Søndergaard L, Estensen ME, Thilén
U, Budts W, Mulder BJ, Blok I,
Tomkiewicz-Pająk L, Szostek K, D’Alto
M, Scognamiglio G, Prokšelj K, Diller
GP, Dimopoulos K, Wort SJ, Gatzoulis
MA. Predictors of death in contempo-
rary adult patients with Eisenmenger
syndrome: a multicenter study. Circula-
tion 2017; 135: 1432–1440.
56. Manes A, Palazzini M, Leci E, Bacchi
Reggiani ML, Branzi A, Galie N. Current
era survival of patients with pulmonary
arterial hypertension associated with
congenital heart disease: a comparison
between clinical subgroups. Eur Heart J
2014; 35: 716–724.
57. Diller G-P, Dimopoulos K, Broberg CS,
Kaya MG, Naghotra US, Uebing A,
Harries C, Goktekin O, Gibbs JS,
Gatzoulis MA. Presentation, survival
prospects, and predictors of death in
Eisenmenger syndrome: a combined ret-
rospective and case-control study. Eur
Heart J 2006; 27: 1737–1742.
58. Chiriac A, Riley DC, Russell M, Moore
JP, Padmanabhan D, Hodge DO, Spiegel
MR, Vargas ER, Phillips SD, Ammash
NM, Madhavan M. Determinants of sud-
den cardiac death in adult patients with
Eisenmenger syndrome. J Am Heart
Assoc 2020; 9: e014554.
59. Khairy P, Landzberg MJ, Gatzoulis MA,
Mercier LA, Fernandes SM, Côté JM,
Lavoie JP, Fournier A, Guerra PG,
Frogoudaki A, Walsh EP, Dore A, Epicar-
dial Versus ENdocardial pacing and
Thromboembolic events Investigators.
Transvenous pacing leads and systemic
thromboemboli in patients with intra-
cardiac shunts: a multicenter study.
Circulation 2006; 113: 2391–2397.
60. Koneru JN, Jones PW, Hammill EF,
Wold N, Ellenbogen KA. Risk factors
and temporal trends of complications as-
sociated with transvenous implantable
cardiac defibrillator leads. J Am Heart
Assoc 2018; 7: e007691.
61. Özcan C, Raunsø J, Lamberts M, Køber
L, Lindhardt TB, Bruun NE, Laursen
ML, Torp-Pedersen C, Gislason GH,
Hansen ML. Infective endocarditis and
risk of death after cardiac implantable
electronic device implantation: a nation-
wide cohort study. Europace 2017; 19:
1007–1014.
62. Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JGF, Coats AJS, Falk
V, González-Juanatey JR, Harjola VP,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske
B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer
P, ESC Scientific Document Group.
2016 ESC guidelines for the diagnosis
and treatment of acute and chronic
heart failure: the Task Force for the di-
agnosis and treatment of acute and
chronic heart failure of the European
Society of Cardiology (ESC) developed
with the special contribution of the
Heart Failure Association (HFA) of the
ESC. Eur Heart J 2016; 37: 2129–2200.
63. Jaarsma T, Beattie JM, Ryder M, Rutten
FH, McDonagh T, Mohacsi P, Murray SA,
Grodzicki T, Bergh I, Metra M, Ekman I,
Angermann C, Leventhal M, Pitsis A,
Anker SD, Gavazzi A, Ponikowski P,
Dickstein K, Delacretaz E, Blue L,
Strasser F, McMurray J, on behalf of
the Advanced Heart Failure Study
Group of the HFA of the ESC. Palliative
care in heart failure: a position state-
ment from the palliative care workshop
of the Heart Failure Association of the
European Society of Cardiology. Eur J
Heart Fail 2009; 11: 433–443.
64. Favoccia C, Kempny A, Yorke J, Arm-
strong I, Price LC, McCabe C, Harries
C, Wort SJ, Dimopoulos K. EmPHasis-
10 score for the assessment of quality
of life in various types of pulmonary hy-
pertension and its relation to outcome.
Eur J Prev Cardiol 2019; 26: 1338–1340.
65. Becker-Grünig T, Klose H, Ehlken N,
Lichtblau M, Nagel C, Fischer C,
Gorenflo M, Tiede H, Schranz D, Hager
A, Kaemmerer H, Miera O, Ulrich S,
Speich R, Uiker S, Grünig E. Efficacy of
exercise training in pulmonary arterial
hypertension associated with congenital
heart disease. Int J Cardiol 2013; 168:
375–381.
66. Tay ELW, Peset A, Papaphylactou M,
Inuzuka R, Alonso-Gonzalez R,
Giannakoulas G, Tzifa A, Goletto S,
Broberg C, Dimopoulos K, Gatzoulis
MA. Replacement therapy for iron defi-
ciency improves exercise capacity and
quality of life in patients with cyanotic
congenital heart disease and/or the
Eisenmenger syndrome. Int J Cardiol
2011; 151: 307–312.
67. Sudore RL, Lum HD, You JJ, Hanson LC,
Meier DE, Pantilat SZ, Matlock DD,
Rietjens JAC, Korfage IJ, Ritchie CS,
Kutner JS, Teno JM, Thomas J,
McMahan RD, Heyland DK. Defining ad-
vance care planning for adults: a consen-
sus definition from a multidisciplinary
Delphi panel. J Pain Symptom Manage
2017; 53: 821–832.e1.
14 A. Constantine et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13263
